公开(公告)号：US20230227917A1

公开(公告)日：2023-07-20

申请号：US17997905

申请日：2021-05-04

Applicant: Hoffmann-La Roche Inc.

Inventor： Stephan Gasser ,  Andreas Roller

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q1/6869

Abstract: The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determing the abundance of stem cell maintenance-related genes in a tumor tissue sample. The abundance of stem cell maintenance-related genes characterized by enhanced expressions of ASPM, CNOT3, LRPS and PBX1 predicts clinical response to the PD-L1 blockade treatment.

公开(公告)号：US11513122B2

公开(公告)日：2022-11-29

申请号：US16362940

申请日：2019-03-25

Applicant: Hoffmann-La Roche Inc.

Inventor： Christian Klein ,  Maud Léa Mayoux ,  Andreas Roller ,  Wei Xu

IPC: G01N33/563 ,  G01N33/574

Abstract: The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determining the abundance of dendritic cells (DCs) in a tumor tissue sample. The abundance of DCs characterized by enhanced expressions of XCR1, IRF8, BATF3 and FLT3 predicts clinical response to the PD-L1 blockade 5 treatment.

公开(公告)号：US20230266324A1

公开(公告)日：2023-08-24

申请号：US18051307

申请日：2022-10-31

Applicant: Hoffmann-La Roche Inc.

Inventor： Christian Klein ,  Maud Léa Mayoux ,  Andreas Roller ,  Wei Xu

IPC: G01N33/574 ,  G01N33/563

CPC classification number: G01N33/57407 ,  G01N33/563

Abstract: The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determining the abundance of dendritic cells (DCs) in a tumor tissue sample. The abundance of DCs characterized by enhanced expressions of XCR1, IRF8, BATF3 and FLT3 predicts clinical response to the PD-L1 blockade treatment.